Table 5.

Overall Summary of Adverse Events by Treatment in the Phase 1 Study (Safety Population^†)

n (%)	Ubrogepant 100 mg (n = 30)	Sumatriptan 100 mg (n = 29)	Ubrogepant 100 mg + Sumatriptan 100 mg (n = 29)	Total‡ (N = 30)
Any TEAE	2 (6.7)	4 (13.8)	0	6 (20.0)
Dry mouth	0	2 (6.9)	0	2 (6.7)
Rhinitis	1 (3.3)	0	0	1 (3.3)
Headache	0	2 (6.9)	0	2 (6.7)
Somnolence	1 (3.3)	0	0	1 (3.3)

TEAE = treatment‐emergent adverse event.

^†One participant discontinued after receiving a single dose of ubrogepant and did not receive sumatriptan alone or in combination with ubrogepant.

^‡Participants who took any study treatment are counted only once in the total. Participants were counted only once within each category.